Literature DB >> 20718714

Antimicrobial resistance 1979-2009 at Karolinska hospital, Sweden: normalized resistance interpretation during a 30-year follow-up on Staphylococcus aureus and Escherichia coli resistance development.

Göran Kronvall1.   

Abstract

To utilize a material of inhibition zone diameter measurements from disc diffusion susceptibility tests between 1979 and 2009, an objective setting of epidemiological breakpoints was necessary because of methodological changes. Normalized resistance interpretation (NRI) met this need and was applied to zone diameter histograms for Staphylococcus aureus and Escherichia coli isolates. The results confirmed a slow resistance development as seen in Northern countries. The S. aureus resistance levels for erythromycin, clindamycin and fusidic acid in 2009 were 3.2%, 1.8% and 1.4% with denominator correction. A rise in resistance to four antimicrobials in 1983 was probably because of a spread of resistant Methicillin Susceptible Staphylococcus Aureus (MSSA). For E. coli, the denominator-corrected resistance levels in 2009 were 27% for ampicillin, around 3% for third-generation cephalosporins, 0.1% for imipenem, 2.5% for gentamicin, 19% for trimethoprim, 4.5% for co-trimoxazole, 1.2% for nitrofurantoin and 9% for ciprofloxacin. The temporal trends showed a rise in fluoroquinolone resistance from 1993, a parallel increase in gentamicin resistance, a substantial increase in trimethoprim and sulphonamide resistance in spite of decreased consumption, and a steady rise in ampicillin resistance from a constant level before 1989. A short review of global resistance surveillance studies is included.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20718714     DOI: 10.1111/j.1600-0463.2010.02660.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  14 in total

1.  Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.

Authors:  Renu Singh; Michelle C Swick; Kimberly R Ledesma; Zhen Yang; Ming Hu; Lynn Zechiedrich; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

2.  Normalized resistance interpretation as a tool for establishing epidemiological MIC susceptibility breakpoints.

Authors:  Göran Kronvall
Journal:  J Clin Microbiol       Date:  2010-10-06       Impact factor: 5.948

Review 3.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 4.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

5.  Bacterial sepsis following prostatic biopsy.

Authors:  Luca Carmignani; Stefano Picozzi; Matteo Spinelli; Salvatore Di Pierro; Gabriella Mombelli; Ercole Negri; Milvana Tejada; Paola Gaia; Elena Costa; Augusto Maggioni
Journal:  Int Urol Nephrol       Date:  2012-02-28       Impact factor: 2.370

6.  A One Health Genomic Investigation of Gentamicin Resistance in Escherichia coli from Human and Chicken Sources in Canada, 2014 to 2017.

Authors:  Graham W Cox; Brent P Avery; E Jane Parmley; Rebecca J Irwin; Richard J Reid-Smith; Anne E Deckert; Rita L Finley; Danielle Daignault; George G Zhanel; Michael R Mulvey; Amrita Bharat
Journal:  Antimicrob Agents Chemother       Date:  2022-09-27       Impact factor: 5.938

7.  Different patterns in use of antibiotics for lower urinary tract infection in institutionalized and home-dwelling elderly: a register-based study.

Authors:  Ylva Haasum; Johan Fastbom; Kristina Johnell
Journal:  Eur J Clin Pharmacol       Date:  2012-08-25       Impact factor: 2.953

8.  Clearance of Staphylococcus aureus from In Vivo Models of Chronic Infection by Immunization Requires Both Planktonic and Biofilm Antigens.

Authors:  Janette M Harro; Yvonne Achermann; Jeffrey A Freiberg; Devon L Allison; Kristen J Brao; Dimitrius P Marinos; Salar Sanjari; Jeff G Leid; Mark E Shirtliff
Journal:  Infect Immun       Date:  2019-12-17       Impact factor: 3.441

9.  Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950-2002.

Authors:  Daniel A Tadesse; Shaohua Zhao; Emily Tong; Sherry Ayers; Aparna Singh; Mary J Bartholomew; Patrick F McDermott
Journal:  Emerg Infect Dis       Date:  2012-05       Impact factor: 6.883

10.  Antimicrobial resistance in commensal Escherichia coli isolated from animals at slaughter.

Authors:  Dariusz Wasyl; Andrzej Hoszowski; Magdalena Zając; Krzysztof Szulowski
Journal:  Front Microbiol       Date:  2013-08-05       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.